Io Biotech Inc (IOBT)

$0.05 +0.02 (48.61%)
Market Cap 2.32M
Revenue (ttm) 0.00
Net Income (ttm) -95.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 18.31
Volume 475,609,094
Avg Vol 14,535,950
Day's Range N/A - N/A
Shares Out 71.95M
Stochastic %K 11%
Beta 0.88
Analysts Sell
Price Target $2.18

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 70 29 80
Address:
Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark
Risktaking
Risktaking Apr. 7 at 4:25 AM
$IOBT Is it too late to get in?
0 · Reply
odieflipper
odieflipper Apr. 7 at 3:57 AM
$IOBT ... Looks as if it Halted @ 7:59 ... not so
0 · Reply
MadMaverick
MadMaverick Apr. 7 at 3:25 AM
$NVDA $AIXI $MLEC $SMX $IOBT New Watchlist now LIVE Get my latest picks 👇🏼 If you have any questions, feel free to DM me.
0 · Reply
Godwins26
Godwins26 Apr. 7 at 3:11 AM
$IOBT
1 · Reply
Godwins26
Godwins26 Apr. 7 at 2:51 AM
$IOBT
0 · Reply
Godwins26
Godwins26 Apr. 7 at 2:50 AM
$IOBT
0 · Reply
Godwins26
Godwins26 Apr. 7 at 2:36 AM
$IOBT
0 · Reply
Godwins26
Godwins26 Apr. 7 at 2:35 AM
$IOBT
0 · Reply
TAE63
TAE63 Apr. 7 at 2:23 AM
$IOBT can be one of those irrational pops before the weekend
0 · Reply
Godwins26
Godwins26 Apr. 7 at 2:22 AM
$IOBT it's going to correct itself 😊
1 · Reply
Latest News on IOBT
IO Biotech Provides Corporate Update

Jan 30, 2026, 8:05 AM EST - 2 months ago

IO Biotech Provides Corporate Update

IO Biotech Announces Exploration of Strategic Alternatives

Jan 21, 2026, 5:30 AM EST - 2 months ago

IO Biotech Announces Exploration of Strategic Alternatives

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

Dec 15, 2025, 4:05 PM EST - 4 months ago

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

IO Biotech Announces Participation in Upcoming December Investor Conferences

Nov 26, 2025, 10:46 AM EST - 4 months ago

IO Biotech Announces Participation in Upcoming December Investor Conferences

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 14, 2025, 8:05 AM EST - 5 months ago

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

IO Biotech Announces Participation in Upcoming Investor Conferences

Nov 12, 2025, 8:30 AM EST - 5 months ago

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 7, 2025, 9:00 AM EST - 5 months ago

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Oct 20, 2025, 2:30 AM EDT - 6 months ago

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Sep 29, 2025, 7:05 AM EDT - 6 months ago

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Sep 23, 2025, 8:05 AM EDT - 6 months ago

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 14, 2025, 4:05 PM EDT - 8 months ago

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

IO Biotech's cancer vaccine shows improvement in late-stage study goal

Aug 11, 2025, 8:24 AM EDT - 8 months ago

IO Biotech's cancer vaccine shows improvement in late-stage study goal

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Aug 11, 2025, 8:00 AM EDT - 8 months ago

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 10, 2025, 8:00 AM EDT - 8 months ago

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 20, 2025, 8:05 AM EDT - 11 months ago

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 8:05 AM EDT - 11 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 26, 2025, 3:05 PM EDT - 1 year ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

Apr 25, 2025, 1:00 PM EDT - 1 year ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:35 PM EDT - 1 year ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Mar 18, 2025, 8:00 AM EDT - 1 year ago

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

IO Biotech Reports 2024 Business Highlights

Mar 4, 2025, 4:17 PM EST - 1 year ago

IO Biotech Reports 2024 Business Highlights

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Feb 23, 2025, 12:07 PM EST - 1 year ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Feb 20, 2025, 8:05 AM EST - 1 year ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Feb 4, 2025, 8:05 AM EST - 1 year ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Jan 9, 2025, 8:05 AM EST - 1 year ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Dec 20, 2024, 8:05 AM EST - 1 year ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 12, 2024, 7:05 AM EST - 1 year ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Nov 7, 2024, 10:00 AM EST - 1 year ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Sep 14, 2024, 2:30 AM EDT - 1 year ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 30, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Aug 13, 2024, 7:05 AM EDT - 1 year ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

Jul 25, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

IO Biotech to Present at Jefferies Global Healthcare Conference

May 23, 2024, 8:30 AM EDT - 2 years ago

IO Biotech to Present at Jefferies Global Healthcare Conference

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

May 14, 2024, 7:55 AM EDT - 2 years ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 4:30 PM EDT - 2 years ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 15, 2024, 8:30 AM EDT - 2 years ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 9, 2024, 12:00 PM EDT - 2 years ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Apr 5, 2024, 8:30 AM EDT - 2 years ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 6, 2024, 4:11 PM EST - 2 years ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Mar 5, 2024, 4:40 PM EST - 2 years ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Feb 26, 2024, 4:05 PM EST - 2 years ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Dec 21, 2023, 8:30 AM EST - 2 years ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:12 AM EST - 2 years ago

IO Biotech Announces 2023 Third Quarter Results

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 13, 2023, 8:00 AM EST - 2 years ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 10, 2023, 8:00 AM EST - 2 years ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Nov 1, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Soci

Oct 23, 2023, 1:00 AM EDT - 2 years ago

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Soci

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 3, 2023, 4:30 PM EDT - 2 years ago

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

Sep 12, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

Risktaking
Risktaking Apr. 7 at 4:25 AM
$IOBT Is it too late to get in?
0 · Reply
odieflipper
odieflipper Apr. 7 at 3:57 AM
$IOBT ... Looks as if it Halted @ 7:59 ... not so
0 · Reply
MadMaverick
MadMaverick Apr. 7 at 3:25 AM
$NVDA $AIXI $MLEC $SMX $IOBT New Watchlist now LIVE Get my latest picks 👇🏼 If you have any questions, feel free to DM me.
0 · Reply
Godwins26
Godwins26 Apr. 7 at 3:11 AM
$IOBT
1 · Reply
Godwins26
Godwins26 Apr. 7 at 2:51 AM
$IOBT
0 · Reply
Godwins26
Godwins26 Apr. 7 at 2:50 AM
$IOBT
0 · Reply
Godwins26
Godwins26 Apr. 7 at 2:36 AM
$IOBT
0 · Reply
Godwins26
Godwins26 Apr. 7 at 2:35 AM
$IOBT
0 · Reply
TAE63
TAE63 Apr. 7 at 2:23 AM
$IOBT can be one of those irrational pops before the weekend
0 · Reply
Godwins26
Godwins26 Apr. 7 at 2:22 AM
$IOBT it's going to correct itself 😊
1 · Reply
Godwins26
Godwins26 Apr. 7 at 2:21 AM
$IOBT yes it will we got warrants are different from options 😊
0 · Reply
JAY_THE_TRADER
JAY_THE_TRADER Apr. 7 at 2:05 AM
$RDGT hold up… this stonk only has 134 mil shares and it’s at .02c ???? Bruh if I had a discord, there would be some squeezing pre r/s pump. Where’s everyone at??? Potential for a good time, not a long time. $AIXI $LNKS $IOBT
1 · Reply
Dinostock69
Dinostock69 Apr. 7 at 1:59 AM
$AMC $BYND $GME $GNS $IOBT IOBT on my trader platform shows 2.75. Can you clarify if the listing is imminent?
1 · Reply
Swatoperator1
Swatoperator1 Apr. 7 at 1:57 AM
$IOBT I tried again placing a sell order but CS is stating that the security is currently unavailable due to reorganization (Chapter 7) by IOBT. I’m glad you were able to sell.
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 7 at 1:52 AM
Treasure Tuesday Watchlist Pt. 2 $AMC $GME $BYND $GNS $IOBT I will look for another 515%+ Runner
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 7 at 1:51 AM
Treasure Tuesday Watchlist Pt. 1 $AIXI $HCAI $IOBT $MIGI $SILO I will look for another 515%+ Runner
0 · Reply
Swatoperator1
Swatoperator1 Apr. 7 at 1:49 AM
$IOBT
1 · Reply
321rip
321rip Apr. 7 at 1:43 AM
$IOBT they have 180 days from notice, 2-12-26, to comply, August 11, 2026, for whatever it's worth
0 · Reply
FlashMcGash
FlashMcGash Apr. 7 at 1:37 AM
$IOBT 1) I was able to put a sell order on Schwab without any issue. 2) stock symbol is stll IOBT not IOBTQ, 3) I don't see anything on OTC Markets or on IO Biotechs website. Just saying I have not found any evidence of delisting.
0 · Reply
Nsk138
Nsk138 Apr. 7 at 1:20 AM
$IOBT we all lost our moneys on this junk!
1 · Reply
Johnhuynh91
Johnhuynh91 Apr. 7 at 1:20 AM
$IOBT this is not letting you sell tomorrow, correct me if im wrong?
2 · Reply
Dinostock69
Dinostock69 Apr. 7 at 1:12 AM
$IOBT mine too. It did what it needed to do. It's going to dilute or perish. Either way it's time to leave this party.
0 · Reply